| 
			
			 More people have died in the United States due to COVID-19 than any 
			other country in the world. With 4% of the world's population, the 
			United States has 20% of all COVID deaths and one of the highest 
			rates of deaths per 100,000 residents, exceeded by only a few 
			countries such as Belgium, the United Kingdom and Italy. (Graphic: 
			https://tmsnrt.rs/34pvUyi) 
 Unlike many countries around the world that had national lockdowns 
			and mask mandates, former U.S. President Donald Trump left public 
			health decisions to state and local governments, resulting in a 
			patchwork of rules that often contradicted the advice of doctors and 
			health officials. Following many maskless yearend holiday 
			gatherings, January became the deadliest month of the pandemic so 
			far with an average of 3,000 people dying every day.
 
			
			 
			With total deaths above 500,000, one in every 673 U.S. residents has 
			succumbed to the pandemic. Global deaths have reached 2.57 million 
			or one out of every 3,000 people on the planet.
 The United States has reported over 28 million cases to date, about 
			25% of all global infections. After peaking at nearly 300,000 new 
			cases in a single day on Jan. 8, the United States is now reporting 
			about 70,000 new infections each day.
 
 However, new variants of the virus threaten to disrupt the path to 
			normalcy.
 
 Officials have also warned that most of these cases are from a more 
			transmissible variant first discovered in the United Kingdom called 
			B.1.1.7, which could become the dominant variant in the United 
			States by March.
 
 Health officials are also worried about a variant first identified 
			in South Africa called 501Y.V2, which has multiple mutations in the 
			important "spike" protein that current vaccines are targeting.
 
 VACCINATIONS: A SILVER LINING
 
 About 15% of the U.S. population has received at least one vaccine 
			dose so far and more than 63 million doses have been administered, 
			according to the Centers for Disease Control and Prevention.
 
			
            [to top of second column] | 
			
			 At the current rate, the United 
								States would take more than nine months or until 
								the end of November this year to vaccinate 75% 
								of the country's population. Even if the current 
								rate doubled, it would still take until early 
								July to vaccinate 75% of residents. 
			In early February, the Biden administration said it is exploring 
			options for increasing manufacturing of Johnson & Johnson's COVID-19 
			vaccine which is one shot and can be stored in a refrigerator. The 
			Pfizer-BioNTech and Moderna Inc vaccines both require two doses and 
			the Pfizer vaccine requires special freezers.
 Johnson & Johnson's vaccine is under review by the U.S. health 
			regulator, and a panel of the Food and Drug Administration's experts 
			are expected to discuss the vaccine's emergency use authorization 
			this week.
 
 However, U.S. President Joe Biden said in early February that it 
			will be difficult for the United States to reach herd immunity, at 
			least 75% of the population inoculated, by the end of this summer.
 
 Vaccine rollout has been challenging as the Trump administration 
			left it up to states to design and implement their own rollout 
			plans. The United States also lacks a national healthcare system and 
			often relies on grocery stores and drug store chains to provide 
			immunizations.
 
 This has led to a growing disparity among states on vaccination 
			progress, including that Blacks and Hispanics are lagging in getting 
			inoculations. In many parts of the country, long lines and hours of 
			waiting was not an uncommon sight.
 
 White House officials said last week that the country has a backlog 
			of 6 million COVID-19 vaccine doses due to inclement weather that 
			swept much of the United States.
 
 (Reporting by Sangameswaran S. in Bengaluru; Editing by Lisa 
			Shumaker)
 
			[© 2021 Thomson Reuters. All rights 
				reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content |